Prokidney Documents
Documents
100
Ticker
PROK
ISIN
US74291D1046
Prokidney SEC Filings
Prokidney Documents 2026
This page contains all official documents and SEC filings for Prokidney stock (PROK, ISIN: US74291D1046). This includes annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transactions (Form 4). Currently 100 documents are available. Data is updated regularly to provide investors with a complete overview of Prokidney's regulatory filings.
Prokidney Stock analysis
Prokidney Prokidney Corp, based in Winston-Salem, North Carolina, is a clinical-stage biotechnology company focused on developing cell therapy platforms for chronic kidney diseases. The company employs 231 people and is listed on the stock market since June 30, 2021. Its lead product, Renal Autologous Cell Therapy (REACT), uses a patient's own kidney cells to preserve kidney function in chronic kidney disease patients. REACT is currently in global Phase 3 trials and multiple Phase 2 trials for diabetic kidney disease.